There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

Maria was distraught after reading about the 'potential'epidemic, yet to happen, and the
horror stories on Facebook needing reassurance and certainty about what she should do …

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …

Background High-efficacy therapies in multiple sclerosis are traditionally used after
unsuccessful treatment with first-line disease modifying therapies. We hypothesised that …

Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …

Background Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid
cells that are implicated in the pathogenesis of multiple sclerosis. Evobrutinib is a selective …

Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …

These updated EBMT guidelines review the clinical evidence, registry activity and
mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple …

Multiple sclerosis (MS) can be divided into four phenotypes based on clinical evolution. The
pathophysiological boundaries of these phenotypes are unclear, limiting treatment …

Chronic active and slowly expanding lesions with smouldering inflammation are
neuropathological correlates of progressive multiple sclerosis pathology. T1 hypointense …